Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer

Published:2017-09-25 Issue:22 Volume:77 Page:6340-6352
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Teo Zhi Ling,Versaci Stephanie,Dushyanthen Sathana,Caramia Franco,Savas Peter,Mintoff Chris P.,Zethoven Magnus,Virassamy Balaji,Luen Stephen J.,McArthur Grant A.,Phillips Wayne A.,Darcy Phillip K.,Loi Sherene

Funder

National Health and Medical Research Council

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.;Cancer Letters;2024-09

2. Signature identification based on immunogenic cell death-related lncRNAs to predict the prognosis and immune activity of patients with endometrial carcinoma;Translational Cancer Research;2024-06

3. A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation;Molecular Cancer;2024-03-14

4. Effect of CDK4/6 Inhibitors on Tumor Immune Microenvironment;Immunological Investigations;2024-02-05

5. CDK4/6 inhibitors in lung cancer: current practice and future directions;European Respiratory Review;2024-01-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP